FDA Licenses Sanofi Pasteur's Pediatric Combination Vaccine, Pentacel
More News related to SNY
- National Transitions of Care Coalition Conducted Information Exchange on the Issue of Transitions of Care
- SAFE-BioPharma Announces Fast, Innovative Identity Proofing Procedure
- Olympic Gymnasts Promote Cancer Awareness Oct. 2 at the Steeplechase Cancer Center
- RainDance Technologies Signs a Collaboration Agreement with sanofi-aventis and Louis Pasteur University to Launch dScreen Consortium within ALSACE BIOVALLEY cluster
- Ben Vereen, Tony Award-Winning Actor, Strives to Raise Awareness of Diabetes and Treatment
More News related to FDA
- Advanced Medical Optics (EYE) Granted FDA Premarket Approval of Healon D(R) Viscoelastic
- GTC Biotherapeutics (GTCB) Announces FDA Accepts ATryn(R) BLA Filing
- Genentech and OSI Phama Said Avastin/Tarceva Combo Fails As Second-Line Treatment For Lung Cancer
Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (NYSE: SNY), announced the U.S. Food and Drug Administration (FDA) has licensed Pentacel, Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate) Vaccine. Pentacel vaccine is indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis, and invasive disease due to Haemophilus influenzae type b (Hib). Pentacel(R) vaccine is approved for use in infants and children 6 weeks through 4 years of age (prior to fifth birthday).
Pentacel vaccine is the first and only four-dose diphtheria, tetanus, and acellular pertussis (DTaP)-based combination vaccine for use in infants and young children in the U.S. that includes both poliovirus and Hib antigens.
Sanofi-Aventis is a pharmaceutical group engaged in the research, development, manufacture and marketing of healthcare products.
Related Categories
FDAStocks Mentioned
-0.54Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
